To the content
3 . 2021

The effectiveness of combined lipid-lowering therapy in patients with disorders of carbohydrate metabolism

Abstract

The search for an optimal therapeutic approach for correcting lipid metabolism disorders in patients with diabetes mellitus in order to increase the effectiveness of therapy and prevent macrovascular complications remains an urgent task at present. Statin monotherapy, even at maximum doses, does not always allow reaching the target values of the lipid profile, namely the level of triglycerides, and therefore it becomes necessary to intensify therapy by adding drugs from other classes, which reduces the compliance of patients. The article describes the main mechanisms of lipid metabolism disorders in patients with obesity and diabetes mellitus, as well as presents the results of studies demonstrating the advantages of combination therapy with rosuvastatin and fenofibrate in the correction of dyslipidemia, which makes it possible to increase the adherence of patients to therapy and reduce the risks of cardiovascular diseases.

Keywords:type 2 diabetes mellitus, triglycerides, fenofibrate, statins

Funding. The study had no sponsor support.

Conflict of interest. The authors declare no conflict of interest.

For citation: Gusenbekova D.G., Ametov A.S. The effectiveness of combined lipid-lowering therapy in patients with disorders of carbohydrate metabolism. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2021; 10 (3): 46-51. DOI: https://doi.org/10.33029/2304-9529-2021-10-3-46-51 (in Russian)

REFERENCES

1. Barrett-Connor E., Orchard T. Diabetes and heart disease. In: National Diabetes Data Group. Diabetes data compiled 1984. Washington: US Department of Health and Human Services, 1985. XVI-XVI-41.

2. Stamler J., Vaccaro O., Neaton J.D., Westworth D. Diabetes and other risk factors and the 12-year cardiovascular mortality for men screened for the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993; 16: 434–44.

3. Zuanetti G., Latini R., Maggioni A.P., et al. Infl uence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study. J Am Coll Cardiol. 1993; 22: 1788–94.

4. Keech A.C., Colquhoun D., Best J., et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care. 2003; 26: 2713–21.

5. Butrova S.A. Obesity. Edited by I.I. Dedov, G.A. Melnichenko. Moscow, 2004: 44 p. (in Russian)

6. Zilov A.V. Obesity. Edited by I.I. Dedov, G.A. Melnichenko. Moscow, 2004: 124-54. (in Russian)

7. Ametov A.S., Tertychnaya E.A. Obesity. Edited by A.S. Ametov. Moscow, 2019: 83 p. (in Russian)

8. Baigent C., Blackwell L., Emberson J., et al. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010; 376 (9753): 1670-81.

9. Fruchart J.C., Sacks F., Hermans M.P., et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol. 2008; 102 (suppl): 1K-34K. DOI: https://doi.org/10.1016/j.amjcard.2008.10.002

10. Sampson U.K., Fazio S., Linton M.F. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep. 2012; 14: 1-10. DOI: https://doi.org/10.1007/s11883-011-0219-7

11. Ridker P.M., Genest J., Boekholdt S.M., et al.; JUPITER Trial Study Group. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet. 2010; 376: 333-9. DOI: https://doi.org/101016/S0140-6736(10)60713-1

12. Kim N.H., Han K.H., Choi J., Lee J., Kim S.G. Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study. BMJ. 2019; 366: l5125. DOI: https://doi.org/10.1136/bmj.15125

13. Elam M.B., et al. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiol. 2017; 2 (4): 370-80. DOI: https://doi.org/10.1001/jamacardio.2016.4828

14. Elam M., Lovato L., Ginsberg H. The ACCORD-Lipid study: implications for treatment of dyslipidemia in type 2 diabetes mellitus. Clin Lipidol. 2011; 6 (1): 9-20.

15. Schoonjans K., Peinado-Onsurbe J., Lefebvre A.M., et al. PPA-Ralpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 1996; 15: 5336-48. DOI: https://doi.org/10.1002/j.1460-2075.1996.tb00918.x

16. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005; 366 (9500): 1849-61. DOI: https://doi.org/10.1016/S0140-6736(05)67667-2

17. Instructions for the medicinal use of the drug Suprozafen from 12/04/2020.

18. Jenkins A.J., Rowley K.G., Lyons T.J., Best J.D., Hill M.A., Klein R.L. Lipoproteins and diabetic microvascular complications. Curr Pharm Des. 2004; 10: 3395-418.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITOR
CHIEF EDITOR
Ametov Alexander S.
Honored Scientist of the Russian Federation, Doctor of Medical Sciences, Professor, Head of Subdepartment of Endocrinology, Head of the UNESCO Network Chair on the subject «Bioethics of diabetes as a global problem» of the Russian Medical Academy of Continuous Professional Education (Moscow)
Вскрытие

Journals of «GEOTAR-Media»